Schiff base gel for preventing adhesions in the abdominal and pelvic cavity, its preparation method and application
Schiff base gel prepared by pre-gel process utilizes a dynamic covalent network formed by aldehyde-modified polysaccharides and amino-modified polysaccharides, and a secondary cross-linking network constructed by ascorbic acid cross-linking sodium hyaluronate. This solves the stability and repair issues of abdominopelvic anti-adhesion products in complex surgical scenarios, achieving long-lasting protection and simplified operation.
Patent Information
- Application Number
- CN202611555903.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-09
- Publication Date
- 2026-11-17
AI Technical Summary
Existing abdominopelvic anti-adhesion products have problems such as mechanical and protective contradictions, insufficient anti-erosion stability, poor wound surface spreading uniformity, lack of tissue repair function and weak anti-displacement ability in complex surgical scenarios. Moreover, the sterilization process bottleneck of traditional Schiff base gel makes industrialization difficult.
Schiff base gels were prepared using a pre-gel process. A dynamic covalent network was formed by aldehyde-modified polysaccharides and amino-modified polysaccharides. A secondary cross-linking network was constructed by cross-linking sodium hyaluronate with ascorbic acid. This provided excellent mechanical strength, tissue adhesion, and erosion resistance. Stabilizers were added to promote tissue repair and adapt to the dynamic physiological environment of the abdominal and pelvic cavity.
It achieves the formation of a stable physical protective barrier on the abdominal and pelvic wound surface, withstands the friction of organ peristalsis and peritoneal fluid flushing, accurately matches the tissue repair cycle, reduces the risk of inflammatory response, simplifies the operation process, adapts to the needs of complex surgeries, and can be mass-produced.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medical polymer materials technology, and relates to a Schiff base gel for preventing adhesions after abdominal and pelvic surgery, its preparation method and application. Background Technology
[0002] Postoperative adhesions of the abdominal and pelvic cavity are a very common postoperative complication in gynecology and general surgery. They are mainly caused by surgical trauma to the abdominal and pelvic cavity, damage to peritoneal mesothelial cells, intraoperative tissue dissection irritation, postoperative local inflammatory exudation, and abnormal deposition of fibrin that cannot be degraded and absorbed in time. They can easily lead to serious sequelae such as chronic abdominal and pelvic pain, fallopian tube torsion and blockage, secondary infertility, recurrent abdominal and pelvic inflammation, and intestinal obstruction. They significantly increase the risk of secondary surgery and treatment costs for patients, and seriously affect the quality of postoperative recovery and long-term prognosis.
[0003] Existing anti-adhesion Schiff base gels for the abdominopelvic cavity mostly employ a "dual-component mixing in-situ gelation" approach. This involves mixing the two components in a solution intraoperatively and applying it to the wound, relying on in-situ curing to form a protective barrier. However, this approach suffers from several drawbacks, including cumbersome operation, uneven mixing during surgery, poor gel stability, easy dilution and leakage of the liquid components by peritoneal fluid and wound bleeding, and uncontrollable gelation time. Furthermore, the abdominopelvic cavity has a complex physiological environment characterized by continuous peritoneal fluid flow, reciprocating peristalsis and friction of the intestines and abdominopelvic organs, and dynamic changes in patient position. Conventional anti-adhesion gels struggle to withstand continuous fluid erosion and mechanical friction, easily detaching, leaking, or breaking down prematurely. Consequently, they cannot maintain a complete physical barrier during the critical wound healing period, resulting in poor stability of the anti-adhesion effect.
[0004] Currently, the most widely used abdominopelvic adhesion prevention product in clinical practice is Bairuiji Hygrigi cross-linked sodium hyaluronate gel. This product is a Class III medical device approved and clinically validated for abdominopelvic adhesion prevention in China. It is suitable for various abdominopelvic laparoscopic and open surgeries, such as ovarian cystectomy, abdominopelvic adhesion lysis, myomectomy, and endometriosis surgery. It achieves basic physical adhesion prevention effect with good biocompatibility. However, it still has unavoidable technical shortcomings in complex abdominopelvic surgical scenarios: ① The contradiction between mechanics and protection is prominent: In order to adapt to the smoothness of clinical injection, the mechanical support strength of the gel is greatly weakened. Faced with the continuous peristalsis and friction of abdominopelvic organs, the protective barrier is easily damaged and fails, and cannot maintain a long-term isolation effect; ② Insufficient erosion stability: The hyaluronic acid matrix itself swells. ① High efficiency and weak hydrolysis resistance: After contact with a large amount of peritoneal fluid, the gel structure quickly loosens and its strength decreases, making it easy to be washed away and lost by the flowing peritoneal fluid. The protection period cannot fully cover the entire peritoneal repair process. ② Poor wound spreading uniformity: The material has limited shear thinning properties. It cannot fully spread and flow on the uneven and scattered surgical wounds in the abdominal and pelvic cavities, which can easily lead to local accumulation, blind spots in wound protection, and insufficient integrity of anti-adhesion coverage. ③ No tissue repair function: Relying solely on physical isolation, it cannot improve the postoperative local inflammatory microenvironment in the abdominal and pelvic cavities and cannot promote the repair of damaged peritoneal tissue. Its function is limited. ④ Weak anti-displacement ability: It lacks tissue adhesion and dynamic self-repair performance. Under the dynamic physiological stress of the abdominal and pelvic cavities, it is easy to break and displace, making it difficult to meet the long-term protection needs of complex abdominal and pelvic surgeries.
[0005] Current research on novel anti-adhesion materials, such as thermosensitive gels and traditional Schiff base in-situ gelling gels, attempts to balance fluidity and mechanical properties through intraoperative solution mixing and in-situ curing at the wound site. However, significant clinical drawbacks remain: additional mixing operations are required during surgery, increasing surgical time and operational errors; the gelling effect is highly dependent on abdominal temperature, pH, and bleeding / exudation levels, resulting in large individual differences, poor gelling stability, and low reproducibility of clinical effects.
[0006] Meanwhile, traditional Schiff base gels suffer from sterilization bottlenecks. Conventional irradiation and moist heat sterilization easily lead to damage to the gel bond structure and performance failure. Aseptic production has high barriers to entry and is difficult to industrialize, hindering large-scale clinical application. Addressing the industry pain points of existing abdominopelvic anti-adhesion products—poor barrier stability, insufficient adaptability, limited functionality, cumbersome operation, and limited industrialization—there is an urgent need to develop a novel Schiff base anti-adhesion gel that is easy to operate, has stable gel formation, is adaptable to the complex physiological environment of the abdominopelvic cavity, combines physical anti-adhesion and tissue repair functions, and can be terminally sterilized. Summary of the Invention
[0007] To address the aforementioned problems in existing technologies, this invention proposes a Schiff base gel for preventing adhesions in the abdominopelvic cavity. It is prepared using a pre-gel process and applied directly during surgery as a finished gel. It is suitable for various abdominopelvic surgery postoperative adhesion prevention scenarios and can effectively solve the defects of existing products, such as unstable barrier, easy loss, lack of repair, and complicated operation.
[0008] A Schiff base gel for preventing adhesions in the abdominopelvic cavity, the raw materials for preparation include: 0.1-4 parts by weight of aldehyde-modified polysaccharide, 2-18 parts by weight of amino-modified polysaccharide, 0.1-0.8 parts by weight of stabilizer, and 0.1-0.7 parts by weight of ascorbic acid cross-linked sodium hyaluronate; the mass ratio of stabilizer to ascorbic acid cross-linked sodium hyaluronate is 1:0.1-3.
[0009] Aldehyde- and amino-modified polysaccharides provide core support strength to the gel through a main network formed by the synergistic action of Schiff base dynamic covalent bonds and physical entanglement. The Schiff base dynamic covalent bonds (imine bonds) reversibly break under intraoperative injection shear force and high strain, causing the gel network to relax and viscosity to decrease rapidly, exhibiting excellent shear-thinning properties. This facilitates smooth injection of endoscopic tubing and uniform spreading of the gel across the wound surface. After the external force is removed, the polymer chains rapidly recover their random entanglement, and the free amino and aldehyde groups quickly reconstruct the imine bonds, achieving second-level self-repair and rapid recovery of viscoelasticity. This immediately forms a complete and stable physical anti-adhesion barrier on the abdominopelvic wound surface, which can withstand organ peristalsis and friction, as well as continuous peritoneal fluid flushing, perfectly adapting to the dynamic physiological environment of the abdominopelvic cavity.
[0010] Ascorbic acid crosslinks with sodium hyaluronate, stabilizers, and amino and aldehyde polysaccharides in the system to synergistically construct a secondary crosslinking network. On the one hand, this effectively reduces the local water activity of the gel, slows down the hydrolytic degradation rate of the gel, and achieves long-term protection of the abdominal and pelvic wounds for 7-14 days, precisely matching the regeneration and repair cycle of peritoneal mesothelial cells. On the other hand, the secondary network can preferentially break and dissipate stress when the gel is subjected to external friction and compression, greatly improving the gel's resistance to deformation and damage, and solving the core shortcomings of traditional hyaluronic acid gels such as insufficient mechanical strength and easy breakage and failure.
[0011] The stabilizer used has excellent tissue compatibility, can specifically support the proliferation and growth of peritoneal epithelial cells, inhibit excessive proliferation of fibroblasts, reduce the formation of fibrous scar tissue, reduce the local inflammatory response in the abdominal and pelvic cavity after surgery, accelerate the epithelialization process of the damaged peritoneal wound, and promote the repair of abdominal and pelvic tissues, thus overcoming the limitations of traditional abdominal and pelvic anti-adhesion gels that only provide physical isolation and have no repair function.
[0012] The hydrogel, incorporating ascorbic acid-crosslinked sodium hyaluronate, achieves multiple benefits including anti-oxidation, anti-inflammation, and wound healing. The ascorbic acid groups effectively eliminate reactive oxygen species (ROS) from postoperative wounds in the abdominopelvic cavity, precisely targeting the peak inflammation period of 3-5 days post-surgery, reducing oxidative stress damage and the risk of postoperative inflammatory adhesions. Simultaneously, the ascorbic acid-crosslinked sodium hyaluronate forms enol-aldehyde conjugated complexes with aldehyde-modified polysaccharides, protecting the Schiff base bond structure through steric hindrance, resisting free radical and water molecule erosion, significantly enhancing the gel's resistance to hydrolysis and aging, and ensuring long-term protective stability in the abdominopelvic cavity. Sodium hyaluronate segments form polyanionic microdomains with the polysaccharide components in the system, enhancing the adhesion between the gel and the peritoneum and organ wounds through interfacial charge reconstruction, effectively resisting peritoneal fluid flushing. Furthermore, it constructs a biomimetic extracellular matrix nanotopology, guiding the orderly attachment, growth, and integration of peritoneal cells, accelerating wound healing.
[0013] For example, the amount of aldehyde polysaccharide is in the range of 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1.0 parts, 2 parts, 3 parts, 4 parts, or any two of these. The amino polysaccharide is in the range of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18 parts or any two of these. The stabilizer is present in a range of 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, or any combination thereof; The ascorbic acid-crosslinked sodium hyaluronate is in the range of 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, or any two of these. The mass ratio of stabilizer to ascorbic acid-crosslinked sodium hyaluronate is in the range of 1:0.1, 1:0.5, 1:1, 1:2, 1:3, or any two of these.
[0014] Preferably, the raw materials for preparing the above-mentioned gel include: 0.4-2 parts by weight of aldehyde polysaccharide, 5-16 parts by weight of amino polysaccharide, 0.3-0.5 parts by weight of stabilizer, and 0.2-0.5 parts by weight of ascorbic acid crosslinked sodium hyaluronate; the mass ratio of stabilizer to ascorbic acid crosslinked sodium hyaluronate is 1:0.5-2.
[0015] In this invention, the stabilizer can competitively bind to the active site of hyaluronic acid degrading enzymes, effectively delaying the hydrolysis process of the gel matrix and prolonging the duration of action of the ascorbic acid functional groups; at the same time, the stabilizer degradation products can competitively bind to cell surface receptors, offsetting the potential fibrotic risk of ascorbic acid cross-linking sodium hyaluronate degradation fragments, thus taking into account both long-term protection and tissue repair safety.
[0016] Furthermore, the mass ratio of the stabilizer to ascorbic acid-crosslinked sodium hyaluronate is 1:0.5-1.8.
[0017] Furthermore, the aldehyde-modified polysaccharide is selected from at least one of oxidized sodium hyaluronate, oxidized sodium alginate, oxidized dextran, oxidized carboxymethyl cellulose, and oxidized chondroitin sulfate.
[0018] Furthermore, the molecular weight of the aldehyde-modified polysaccharide is 50-500 kDa, and the degree of substitution is 20-80%.
[0019] Furthermore, the molecular weight of the aldehyde-modified polysaccharide is 100-200 kDa, and the degree of substitution is 30-70%.
[0020] Furthermore, the amino-modified polysaccharide is selected from at least one of chitosan, carboxymethyl chitosan, hydroxypropyl chitosan, and hydroxypropylmethyl chitosan.
[0021] Furthermore, the molecular weight of the amino-modified polysaccharide is 40-500 kDa, and the degree of substitution is 40-95%.
[0022] Furthermore, the molecular weight of the amino-modified polysaccharide is 50-200 kDa, and the degree of substitution is 65-90%.
[0023] Furthermore, the stabilizer is selected from at least one of chondroitin sulfate, sodium alginate, trehalose, sodium carboxymethyl cellulose, and sulfated fucoidan.
[0024] Furthermore, the molecular weight of ascorbic acid crosslinked sodium hyaluronate is 100-1000 kDa, and the degree of substitution is 5-50%.
[0025] Furthermore, the molecular weight of ascorbic acid crosslinked sodium hyaluronate is 200-700 kDa, and the degree of substitution is 10-35%.
[0026] Furthermore, the raw materials for preparing Schiff base gel also include a solvent, which is selected from at least one of water for injection, physiological saline, and PBS buffer.
[0027] Furthermore, in the gel system, the proportion of aldehyde polysaccharide is 0.3-1.3 wt%, the proportion of amino polysaccharide is 3-12 wt%, the proportion of stabilizer is 0.1-0.6 wt%, the proportion of ascorbic acid crosslinked sodium hyaluronate is 0.1-0.5 wt%, and the remainder is solvent.
[0028] A method for preparing Schiff base gel for preventing adhesions in the abdominopelvic cavity includes the following steps: S1. Add the aldehyde-modified polysaccharide, ascorbic acid-crosslinked sodium hyaluronate, and stabilizer sequentially to a portion of the solvent and stir thoroughly to obtain mixture A; add the amino-modified polysaccharide to the remaining solvent and stir thoroughly to obtain solution B; S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution.
[0029] S3. The prepolymer solution is filled, allowed to stand, and sterilized to obtain Schiff base gel.
[0030] Furthermore, in step S1, the stirring time for preparing mixture A is 2-6 hours, and the entire process is conducted in the dark.
[0031] Furthermore, in step S1, the stirring time for solution B is 3-8 hours.
[0032] Further, in step S3, filling includes: filling the prepolymer liquid into a pre-filled syringe, wherein the syringe is made of glass or polymer material.
[0033] Furthermore, in step S3, the settling time is 20-30 hours.
[0034] Further, in step S3, sterilization includes: transferring the settled sample to an irradiation sterilization chamber and performing terminal sterilization using cobalt-60 (γ-rays) or an electron beam (E-beam).
[0035] Furthermore, in step S3, the irradiated absorbed dose during sterilization is 10-25 kGy, preferably 15-20 kGy, to ensure the product reaches a sterility assurance level (SAL) ≤ 10. -6 That's all.
[0036] Furthermore, in step S3, the sterilized sample is stored at 2-8°C in the dark for at least 24 hours to completely eliminate residual free radicals from irradiation, ensuring the stability of the gel structure and the safety of its use.
[0037] The aforementioned Schiff base gel for preventing adhesions in the abdominal and pelvic cavities is applied to postoperative anti-adhesion care for various abdominal and pelvic surgeries.
[0038] Furthermore, the specific application method of the above-mentioned Schiff base gel after abdominoplasty is as follows: After hemostasis and wound cleaning are completed in abdominoplasty, under the assistance of laparoscopy or open surgery, the pre-formed gel is evenly applied to all damaged tissue surfaces such as peritoneal wounds, ovarian wounds, uterine serosal surfaces, fallopian tube surgical wounds, and pelvic wall dissection wounds using a syringe and laparoscopic extension tube. Relying on the excellent adhesion and spreading properties of the gel, a full-coverage physical protective barrier is quickly formed, achieving the dual effects of anti-adhesion and wound repair.
[0039] Furthermore, the aforementioned abdominal and pelvic surgeries include various gynecological minimally invasive and open abdominal and pelvic surgeries such as abdominal and pelvic adhesion lysis, ovarian cyst removal, endometriosis lesion resection, uterine fibroid removal, and fallopian tube repair.
[0040] Furthermore, the specific amount of Schiff base gel applied is dynamically adjusted according to the extent and number of surgical wounds in the abdominal and pelvic cavity, adapting to the needs of different surgical wounds.
[0041] Furthermore, this gel is suitable for large-area, scattered, and irregular abdominal and pelvic surgical wounds, and its clinical compatibility is far superior to traditional single hyaluronic acid gel products.
[0042] The beneficial effects of this invention are: ① The Schiff base gel prepared by this invention, through the synergistic cross-linking of multiple components, possesses excellent mechanical strength, tissue adhesion, erosion resistance, and dynamic self-repair capability. It can closely adhere to various irregular surgical wounds in the abdominal and pelvic cavities, effectively resisting the continuous flushing of peritoneal fluid and the reciprocating peristaltic friction of organs, and stably maintaining a long-term physical isolation barrier. This completely solves the technical defects of traditional cross-linked hyaluronic acid gels such as insufficient mechanical strength, easy breakage and loss, and insufficient protection period. At the same time, it can accurately remove postoperative inflammatory free radicals, cover the 3-5 day postoperative inflammatory outbreak period in the abdominal and pelvic cavities, reduce local inflammatory reactions, and reduce the risk of adhesion and infection, thus having the dual effects of preventing adhesion and promoting repair.
[0043] ② This invention adopts a pre-formed gel process, which eliminates the need for on-site mixing and proportioning during surgery and waiting for in-situ gel formation. The operation can be completed in a single step by injection and application. Compared with traditional two-component in-situ gel products and Bairuiji hyaluronic acid gel, it greatly simplifies the intraoperative operation process, shortens the surgical assistance time, avoids clinical risks such as uneven mixing, unstable gel formation, and drug leakage, and is suitable for the rhythm of various abdominal and pelvic surgeries such as laparoscopy and open surgery, making it more clinically practical.
[0044] ③The raw materials used in this invention are all natural polymer materials with excellent biocompatibility. They are non-toxic and non-irritating. The degradation products can be absorbed by the human body through normal metabolism. There is no risk of foreign body residue in the abdominal and pelvic cavities. They will not interfere with the normal healing process of abdominal and pelvic tissues. They have extremely high biocompatibility and are superior to some traditional anti-adhesion gel products with single functions and potential risks of interfering with healing.
[0045] ④ The process conditions of this invention are mild and the process is simple. It can achieve sterilization by cobalt-60 or electron beam terminal irradiation, which completely solves the pain points of traditional Schiff base gel sterilization difficulties, high cost of aseptic control and limited industrialization. It can be mass-produced on a large scale, the production cost is controllable, and it is convenient for clinical popularization and promotion in primary hospitals and medical institutions at all levels.
[0046] ⑤ The degradation cycle of the gel in this invention is stably maintained at 10-13.5 days, which precisely matches the 7-14 day regeneration and repair cycle of peritoneal mesothelial cells. It provides continuous protection during the critical period of wound repair. After the wound heals, it is automatically degraded and absorbed without residue and does not affect the normal physiological function of the abdominal and pelvic cavity. The anti-adhesion efficacy is significantly higher than that of conventional hyaluronic acid gel products in clinical practice, and the clinical benefits are more significant. Detailed Implementation
[0047] To make the above-mentioned objects, features, and advantages of the present invention more apparent and understandable, specific embodiments of the present invention are described in detail below. Many specific details are set forth in the following description to provide a thorough understanding of the present invention. However, the present invention can be practiced in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.
[0048] Unless otherwise shown or indicated in the operational embodiments, all figures used to represent the amounts, physicochemical properties, etc., of ingredients in the specification and claims are to be understood to be adjusted by the term "about" in all cases. Therefore, unless stated to the contrary, the numerical parameters listed in the foregoing specification and appended claims are approximations, and those skilled in the art can appropriately modify these approximations to obtain the desired characteristics by utilizing the teachings disclosed herein. The use of numerical ranges expressed as endpoints includes all numbers within that range and any range within that range; for example, 1 to 5 includes 1, 1.1, 1.3, 1.5, 2, 2.75, 3, 3.80, 4, and 5, etc.
[0049] One embodiment of the present invention provides a Schiff base gel for preventing adhesions in the abdominopelvic cavity. The raw materials for preparation include: 0.1-4 parts by weight of aldehyde-modified polysaccharide, 2-18 parts by weight of amino-modified polysaccharide, 0.1-0.8 parts by weight of stabilizer, and 0.1-0.7 parts by weight of ascorbic acid crosslinked sodium hyaluronate; the mass ratio of stabilizer to ascorbic acid crosslinked sodium hyaluronate is 1:0.1-3.
[0050] In some embodiments, the raw materials for preparing the gel include: 0.4-2 parts by weight of aldehyde polysaccharide, 5-16 parts by weight of amino polysaccharide, 0.3-0.5 parts by weight of stabilizer, and 0.2-0.5 parts by weight of ascorbic acid crosslinked sodium hyaluronate; the mass ratio of stabilizer to ascorbic acid crosslinked sodium hyaluronate is 1:0.5-1.8.
[0051] In some embodiments, the aldehyde-modified polysaccharide is selected from at least one of oxidized sodium hyaluronate, oxidized sodium alginate, oxidized dextran, oxidized carboxymethyl cellulose, and oxidized chondroitin sulfate.
[0052] In some embodiments, the molecular weight of the aldehyde polysaccharide is 50-500 kDa and the degree of substitution is 20-80%.
[0053] In some embodiments, the molecular weight of the aldehyde-modified polysaccharide is 100-200 kDa and the degree of substitution is 30-70%.
[0054] In some embodiments, the amino polysaccharide is selected from at least one of chitosan, carboxymethyl chitosan, hydroxypropyl chitosan, and hydroxypropylmethyl chitosan.
[0055] In some embodiments, the aminopolysaccharide has a molecular weight of 40-500 kDa and a degree of substitution of 40-95%.
[0056] In some embodiments, the aminopolysaccharide has a molecular weight of 50-200 kDa and a degree of substitution of 65-90%.
[0057] In some embodiments, the stabilizer is selected from at least one of chondroitin sulfate, sodium alginate, trehalose, sodium carboxymethyl cellulose, and sulfated fucoidan.
[0058] In some embodiments, the molecular weight of ascorbic acid crosslinked sodium hyaluronate is 100-1000 kDa and the degree of substitution is 5-50%.
[0059] In some embodiments, the molecular weight of ascorbic acid crosslinked sodium hyaluronate is 200-700 kDa and the degree of substitution is 10-35%.
[0060] In some embodiments, the raw materials for preparing Schiff base gels also include a solvent, and the solvent used is selected from at least one of water for injection, physiological saline, and PBS buffer.
[0061] In some embodiments, the gel system comprises 0.3-1.3 wt% aldehyde polysaccharide, 3-12 wt% amino polysaccharide, 0.1-0.6 wt% stabilizer, 0.1-0.5 wt% ascorbic acid crosslinked sodium hyaluronate, and the remainder being solvent.
[0062] A method for preparing Schiff base gel for preventing adhesions in the abdominopelvic cavity includes the following steps: S1. Add the aldehyde-modified polysaccharide, ascorbic acid-crosslinked sodium hyaluronate, and stabilizer sequentially to a portion of the solvent and stir thoroughly to obtain mixture A; add the amino-modified polysaccharide to the remaining solvent and stir thoroughly to obtain solution B; In some embodiments, the stirring time for preparing mixture A is 2-6 hours, and the entire process is conducted in the dark.
[0063] In some embodiments, the stirring time for solution B is 3-8 hours.
[0064] S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution.
[0065] S3. The prepolymer solution is filled, allowed to stand, and sterilized to obtain Schiff base gel.
[0066] In some embodiments, filling includes: filling a prepolymer liquid into a pre-filled medical syringe made of polymer material.
[0067] In some embodiments, the settling time is 20-30 hours.
[0068] In some embodiments, sterilization includes: transferring the settled sample to an irradiation sterilization chamber and performing terminal sterilization using cobalt-60 (gamma rays) or an electron beam (E-beam).
[0069] In some embodiments, the irradiated absorbed dose during the sterilization process is 10-25 kGy, preferably 15-20 kGy.
[0070] In some embodiments, sterilized samples are stored at 2-8°C in the dark for at least 24 hours.
[0071] The aforementioned Schiff base gel for preventing adhesions in the abdominal and pelvic cavities is used for postoperative anti-adhesion care in various abdominal and pelvic surgeries.
[0072] In some embodiments, the specific application method of the above-mentioned Schiff base gel after abdominal and pelvic surgery is as follows: after abdominal and pelvic surgery, under the assistance of laparoscopy or open surgery, the hydrogel is evenly applied to the surgical wound of the abdominal and pelvic cavity using a syringe and extension tube to achieve full coverage and anti-adhesion protection.
[0073] In some embodiments, abdominopelvic surgery includes gynecological abdominopelvic surgeries such as abdominopelvic adhesion lysis, ovarian cyst removal, endometriosis lesion resection, myomectomy, and fallopian tube reconstruction.
[0074] In some embodiments, the specific amount of Schiff base gel applied is dynamically adjusted according to the size and extent of the abdominal and pelvic wound to adapt to various surgical scenarios.
[0075] Example The following examples describe the disclosure of this invention in more detail. These examples are merely illustrative, as various modifications and variations will be apparent to those skilled in the art within the scope of this disclosure. Unless otherwise stated, all parts, percentages, and ratios reported in the following examples are based on weight, and all reagents used in the examples are commercially available or synthesized by conventional methods and can be used directly without further processing. The instruments used in the examples are also commercially available.
[0076] Example 1 The preparation method of Schiff base gel for preventing adhesions in the abdominopelvic cavity includes the following steps: S1. 0.7 parts of aldehyde-modified polysaccharide oxidized sodium hyaluronate (molecular weight 150kDa, degree of substitution 50%), 0.3 parts of ascorbic acid cross-linked sodium hyaluronate (molecular weight 500kDa, degree of substitution 15%), and 0.4 parts of stabilizer chondroitin sulfate were sequentially added to 25 parts of solvent water for injection and stirred for 4 hours to obtain a transparent mixture A; 7 parts of amino-modified polysaccharide carboxymethyl chitosan (molecular weight 100kDa, degree of substitution 85%) were added to 66.8 parts of solvent water for injection and stirred for 6 hours to obtain solution B; the total amount of solvent used to prepare mixture A and solution B was 91.8 parts.
[0077] S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution; S3. Fill the prepolymer solution into a pre-filled medical syringe made of polymer material; after standing for 24 hours, transfer it to an irradiation sterilization chamber and perform terminal sterilization using cobalt-60 (γ-rays). The irradiation absorbed dose during the sterilization process is 18 kGy. After sterilization, store the sample at 4°C in the dark for 24 hours.
[0078] Calculations show that sodium oxyhyaluronate accounts for 0.699 wt% of the raw materials used in the preparation of Schiff base gel, carboxymethyl chitosan accounts for 6.986 wt%, chondroitin sulfate accounts for 0.399 wt%, ascorbic acid-crosslinked sodium hyaluronate accounts for 0.299 wt%, and water for injection accounts for 91.617 wt%. The mass ratio of chondroitin sulfate to ascorbic acid-crosslinked sodium hyaluronate is 1:0.75.
[0079] Example 2 The preparation method of Schiff base gel for preventing adhesions in the abdominopelvic cavity includes the following steps: S1. Add 0.4 parts of aldehyde-modified polysaccharide oxidized sodium hyaluronate (molecular weight 150kDa, degree of substitution 50%), 0.2 parts of ascorbic acid crosslinked sodium hyaluronate (molecular weight 500kDa, degree of substitution 15%), and 0.5 parts of stabilizer chondroitin sulfate to 20 parts of solvent water for injection, stir for 3 hours, and obtain a transparent mixture A; add 15.8 parts of amino-modified polysaccharide carboxymethyl chitosan (molecular weight 100kDa, degree of substitution 85%) to 90 parts of solvent water for injection, stir for 4 hours, and obtain solution B; the total amount of solvent used to prepare mixture A and solution B is 110 parts.
[0080] S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution; S3. Fill the prepolymer solution into a pre-filled medical syringe made of polymer material; after standing for 24 hours, transfer it to an irradiation sterilization chamber and perform terminal sterilization using cobalt-60 (γ-rays). The irradiation absorbed dose during the sterilization process is 15 kGy. After sterilization, store the sample at 8°C in the dark for 24 hours.
[0081] Calculations show that sodium oxyhyaluronate accounts for 0.303 wt% of the raw materials used in the preparation of Schiff base gel, carboxymethyl chitosan accounts for 11.979 wt%, chondroitin sulfate accounts for 0.379 wt%, ascorbic acid-crosslinked sodium hyaluronate accounts for 0.152 wt%, and water for injection accounts for 87.187 wt%. The mass ratio of chondroitin sulfate to ascorbic acid-crosslinked sodium hyaluronate is 1:0.4.
[0082] Example 3 The preparation method of Schiff base gel for preventing adhesions in the abdominopelvic cavity includes the following steps: S1. Two parts of aldehyde-modified polysaccharide oxidized sodium hyaluronate (molecular weight 150 kDa, degree of substitution 50%), 0.5 parts of ascorbic acid cross-linked sodium hyaluronate (molecular weight 500 kDa, degree of substitution 15%), and 0.3 parts of stabilizer chondroitin sulfate were sequentially added to 90 parts of solvent water for injection and stirred for 6 hours to obtain a transparent mixture A; five parts of amino-modified polysaccharide carboxymethyl chitosan (molecular weight 100 kDa, degree of substitution 85%) were added to 67 parts of solvent water for injection and stirred for 8 hours to obtain solution B; the total amount of solvent used to prepare mixture A and solution B was 157 parts.
[0083] S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution; S3. Fill the prepolymer solution into a pre-filled medical syringe made of polymer material; after standing for 24 hours, transfer it to an irradiation sterilization chamber and perform terminal sterilization using cobalt-60 (γ-rays). The irradiation absorbed dose during the sterilization process is 20 kGy. After sterilization, store the sample at 2°C in the dark for 24 hours.
[0084] Calculations show that sodium oxyhyaluronate accounts for 1.214 wt% of the raw materials used in the preparation of Schiff base gel, carboxymethyl chitosan accounts for 3.034 wt%, chondroitin sulfate accounts for 0.182 wt%, ascorbic acid cross-linked sodium hyaluronate accounts for 0.303 wt%, and water for injection accounts for 95.267 wt%. The mass ratio of chondroitin sulfate to ascorbic acid cross-linked sodium hyaluronate is 1:1.67.
[0085] Example 4 Example 4 is basically the same as Example 1, the main difference being that in Example 4, chondroitin sulfate is 0.6 parts and ascorbic acid cross-linked sodium hyaluronate is 0.1 parts. Calculations show that chondroitin sulfate accounts for 0.599 wt% of the raw materials for preparing Schiff base gel, and ascorbic acid cross-linked sodium hyaluronate accounts for 0.100 wt%, with a mass ratio of chondroitin sulfate to ascorbic acid cross-linked sodium hyaluronate of 1:0.17.
[0086] Example 5 Example 5 is basically the same as Example 1, the main difference being that in Example 5, chondroitin sulfate is 0.2 parts and ascorbic acid cross-linked sodium hyaluronate is 0.5 parts. Calculations show that chondroitin sulfate accounts for 0.200 wt% of the raw materials for Schiff base gel preparation, ascorbic acid cross-linked sodium hyaluronate accounts for 0.499 wt%, and the mass ratio of chondroitin sulfate to ascorbic acid cross-linked sodium hyaluronate is 1:2.5.
[0087] Comparative Example 1 Comparative Example 1 is basically the same as Example 1, the main difference being that in Comparative Example 1, ascorbic acid is used instead of sodium ascorbic acid crosslinked with sodium hyaluronate in Example 1.
[0088] Comparative Example 2 Comparative Example 2 is basically the same as Example 1, the main difference being that no ascorbic acid cross-linked sodium hyaluronate was added in Comparative Example 2, that is, the amount of ascorbic acid cross-linked sodium hyaluronate was 0. Specifically, the raw materials for preparing the gel included: 0.7 parts of aldehyde-modified polysaccharide oxidized sodium hyaluronate, 7 parts of amino-modified polysaccharide carboxymethyl chitosan, 0.7 parts of stabilizer chondroitin sulfate, and 91.8 parts of water for injection.
[0089] Comparative Example 3 Comparative Example 3 is basically the same as Example 1, the main difference being that no chondroitin sulfate was added in Comparative Example 3, that is, the amount of chondroitin sulfate was 0. Specifically, the raw materials for preparing the gel included: 0.7 parts of aldehyde-modified polysaccharide oxidized sodium hyaluronate, 7 parts of amino-modified polysaccharide carboxymethyl chitosan, 0.7 parts of ascorbic acid crosslinked sodium hyaluronate, and 91.8 parts of water for injection.
[0090] Comparative Example 4 Comparative Example 4 is basically the same as Example 1, the main difference being that in Comparative Example 4, 0.018 parts of ascorbic acid and 0.282 parts of sodium hyaluronate are used instead of 0.3 parts of ascorbic acid-crosslinked sodium hyaluronate in Example 1. The specific preparation steps of the gel include: S1. 0.7 parts of aldehyde-modified polysaccharide oxidized sodium hyaluronate (molecular weight 150kDa, degree of substitution 50%), 0.014 parts of ascorbic acid, 0.286 parts of sodium hyaluronate, and 0.4 parts of stabilizer chondroitin sulfate were sequentially added to 25 parts of solvent water for injection and stirred for 4 hours to obtain a transparent mixture A; 7 parts of amino-modified polysaccharide carboxymethyl chitosan (molecular weight 100kDa, degree of substitution 85%) were added to 66.8 parts of solvent water for injection and stirred for 6 hours to obtain solution B; the total amount of solvent used to prepare mixture A and solution B was 91.8 parts.
[0091] S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution; S3. Fill the prepolymer solution into a pre-filled medical syringe made of polymer material; after standing for 24 hours, transfer it to an irradiation sterilization chamber and perform terminal sterilization using cobalt-60 (γ-rays). The irradiation absorbed dose during the sterilization process is 18 kGy. After sterilization, store the sample at 4°C in the dark for 24 hours.
[0092] The above embodiments are only for illustrating the technical concept and features of the present invention. Their purpose is to enable those skilled in the art to understand the content of the present invention and implement it. They should not be used to limit the scope of protection of the present invention. All equivalent changes or modifications made in accordance with the spirit and essence of the present invention should be covered within the scope of protection of the present invention.
[0093] Performance testing The gels prepared in Examples 1-5 and Comparative Examples 1-4 were tested as follows: 1. Compression strength test: The compression strength of the gel was tested using a rheometer at a speed of 200 μm / s. The pressure (Fb, unit N) when the gel was compressed to the point of rupture was recorded. The compression strength was calculated based on the contact area (St, unit mm²) using the following formula: Compression strength = Fb / St, unit kPa.
[0094] 2. Adhesion strength test: Place the gel between two pieces of pigskin and apply pressure with a 200g weight for 10 minutes. Then, clamp the two pieces of pigskin onto the two clamps of a universal tensile testing machine and test the maximum force value of separation (Fmax, unit N). Calculate the adhesion strength based on the adhesion area (Sa, unit cm²) using the following formula: Adhesion strength = Fmax / Sa, unit kPa.
[0095] 3. Gel swelling test: Record the initial mass m0 of the gel, place it in PBS buffer at pH 7.4, and swell it in a water bath shaker at 37℃ and 30 rpm for 24 h. Weigh the swollen gel mass m1. The degree of gel swelling after 24 h is calculated as (m1 - m0) / m0, with units of m0.
[0096] 4. In vitro degradation test: Record the initial mass m0 of the gel, immerse the gel in PBS buffer at pH 7.4, and place it in a water bath shaker at 37℃ and 30 rpm for in vitro degradation. Record the time required for complete degradation, which is the complete degradation time.
[0097] 5. Vitamin C Release Test: Vitamin C standard was tested for absorbance at 265 nm to establish a concentration-absorbance standard curve. The gel was immersed in a PBS buffer solution containing metaphosphate (pH=3) and placed in a water bath at 37℃ and 30 rpm. Every 0.5 days, the PBS buffer solution containing metaphosphate was tested for UV absorbance. The vitamin C concentration was determined based on the standard curve until the calculated vitamin C mass was close to the initial vitamin C dosage and the absorbance stabilized. This time was the time required for complete vitamin C release.
[0098] The test results are shown in the table below.
[0099]
[0100] The results above show that the Schiff base gels obtained in Examples 1-5 have a compressive strength of 9.6-14.3 kPa, an adhesive strength of 7.1-10.5 kPa, a 24-hour swelling rate of 18-26%, a complete gel degradation time of 10.5-13.5 days, and a complete VC release time of 3-5 days. They can effectively adhere to the peritoneum and organ wounds in the abdominopelvic cavity, possessing excellent anti-erosion and anti-friction properties, suitable mechanical support, and degradation characteristics that precisely match the peritoneal repair cycle. They can effectively prevent postoperative adhesions in the abdominopelvic cavity, while also releasing antioxidant active ingredients for a long time, covering the high incidence period of postoperative inflammation, and significantly reducing the risk of abdominopelvic inflammation and adhesions. Their overall performance is significantly better than traditional single hyaluronic acid abdominopelvic anti-adhesion gels.
[0101] Compared to Example 1, Example 4 and Comparative Example 2 show that supplementing the reduced or absent amount of ascorbic acid-crosslinked sodium hyaluronate with chondroitin sulfate, i.e., increasing the proportion of chondroitin sulfate, is detrimental to the optimization of gel compressive strength, adhesive strength, swelling rate, complete gel degradation time, and complete VC release time. The reasons may be as follows: Reduced or absent addition of ascorbic acid-crosslinked sodium hyaluronate leads to a sparser or non-existent secondary network formed by it with stabilizers, amino-modified polysaccharides, and aldehyde-modified polysaccharides, weakening its external stress dissipation capacity and thus reducing gel compressive strength. Simultaneously, the total amount of polyanionic microdomains formed with aldehyde-modified polysaccharides and stabilizers, as well as the total amount of nanostructures formed with stabilizers, decreases, thus reducing gel adhesive strength. Furthermore, it reduces or eliminates the introduction of rigid ascorbic acid groups, affecting both the gel's hydrolysis resistance and its anti-inflammatory ability. Therefore, the swelling rate of the gel increases after 24 hours and the time for complete release of vitamin C is shortened. In addition, due to the decrease in the mechanical properties and hydrolysis resistance of the gel, water molecules can easily penetrate into the gel, which accelerates its degradation rate. Therefore, the time for complete degradation of the gel is also shortened.
[0102] Compared with Example 1, Example 5 and Comparative Example 3 show that when ascorbic acid cross-linked sodium hyaluronate is used to supplement the amount of chondroitin sulfate that has been reduced or not added, the proportion of ascorbic acid cross-linked sodium hyaluronate in the system increases. Although this helps to reduce the gel swelling rate, it is not conducive to improving the gel compressive strength, adhesive strength, gel complete degradation time, and VC complete release time. The reasons may be as follows: Reduced or absent addition of chondroitin sulfate leads to a sparser or non-existent secondary network formed by its interaction with ascorbic acid-crosslinked sodium hyaluronate and the synergistic aminopolysaccharides and ascorbic acid-crosslinked hyaluronic acid, which is detrimental to improving gel compressive strength. Simultaneously, insufficient chondroitin sulfate in the system interacts with ascorbic acid-crosslinked sodium hyaluronate and aldehyde-modified polysaccharides to form sufficient polyanionic microdomains and nanostructures, thus reducing gel adhesion strength. Furthermore, reduced or absent chondroitin sulfate also decreases the total amount of hyaluronic acid-degrading enzymes it consumes, accelerating the hydrolysis of sodium hyaluronate, thus shortening the complete degradation time of the gel and the complete release time of vitamin C. However, due to the increased amount of ascorbic acid-crosslinked sodium hyaluronate in the system, there are more rigid ascorbic acid groups in the gel, which enhances the water resistance in the early stage of gelation, thus reducing the 24-hour swelling rate of the gel.
[0103] Compared with Example 1, Comparative Examples 1 and 4 show that using ascorbic acid or a physical mixture of ascorbic acid and sodium hyaluronate to replace ascorbic acid-crosslinked sodium hyaluronate fails to achieve good gel performance. This may be because: ascorbic acid cannot synergistically form a secondary network with chondroitin sulfate and amino- and aldehyde-modified polysaccharides in the system, providing only weak physical filling. Its mechanical strengthening effect is far inferior to that of ascorbic acid-crosslinked sodium hyaluronate, resulting in a significant decrease in gel compressive strength. Simultaneously, it cannot form polyanionic microdomains and nanostructures in the system, leading to weak tissue binding and easy displacement of the gel, thus significantly reducing gel adhesion strength. Furthermore, ascorbic acid is easily oxidized, rapidly diffuses after injection, and is completely released within a short time, failing to impart long-term hydrolysis resistance to the gel and failing to achieve long-term sustained release through gel encapsulation. Therefore, the swelling rate of the gel increases significantly, and the complete degradation time and complete VC release time decrease drastically. Overall performance is far inferior to the compound system of this invention and significantly lags behind the abdominopelvic anti-adhesion performance standards required for clinical applications.
Claims
1. A Schiff base gel for preventing adhesions in the abdominal and pelvic cavity, characterized in that, The raw materials for preparing the gel include: 0.1-4 parts by weight of aldehyde polysaccharide, 2-18 parts by weight of amino polysaccharide, 0.1-0.8 parts by weight of stabilizer, and 0.1-0.7 parts by weight of ascorbic acid crosslinked sodium hyaluronate; The mass ratio of the stabilizer to the ascorbic acid-crosslinked sodium hyaluronate is 1:0.1-3.
2. The Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 1, characterized in that, The raw materials for preparing the gel include: 0.4-2 parts by weight of aldehyde-modified polysaccharide, 5-16 parts by weight of amino-modified polysaccharide, 0.3-0.5 parts by weight of stabilizer, and 0.2-0.5 parts by weight of ascorbic acid crosslinked sodium hyaluronate; the mass ratio of the stabilizer to the ascorbic acid crosslinked sodium hyaluronate is 1:0.5-2.
3. The Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 1, characterized in that, The aldehyde-modified polysaccharide is selected from at least one of oxidized sodium hyaluronate, oxidized sodium alginate, oxidized dextran, oxidized carboxymethyl cellulose, and oxidized chondroitin sulfate. The amino-modified polysaccharide is selected from at least one of chitosan, carboxymethyl chitosan, hydroxypropyl chitosan, and hydroxypropylmethyl chitosan; The stabilizer is selected from at least one of chondroitin sulfate, sodium alginate, trehalose, sodium carboxymethyl cellulose, and sulfated fucoidan.
4. The Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 1, characterized in that, The aldehyde-modified polysaccharide has a molecular weight of 50-500 kDa and a degree of substitution of 20-80%. The amino-modified polysaccharide has a molecular weight of 40-500 kDa and a degree of substitution of 40-95%. The ascorbic acid crosslinked sodium hyaluronate has a molecular weight of 100-1000 kDa and a degree of substitution of 5-50%.
5. The Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 4, characterized in that, The aldehyde-modified polysaccharide has a molecular weight of 100-200 kDa and a degree of substitution of 30-70%. The amino-modified polysaccharide has a molecular weight of 50-200 kDa and a degree of substitution of 65-90%. The ascorbic acid crosslinked sodium hyaluronate has a molecular weight of 200-700 kDa and a degree of substitution of 10-35%.
6. The Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 1, characterized in that, The raw materials for preparing the Schiff base gel also include a solvent, which is selected from at least one of water for injection, physiological saline, and PBS buffer.
7. The method for preparing Schiff base gel for preventing adhesions in the abdominopelvic cavity according to any one of claims 1-6, characterized in that, Includes the following steps: S1. Add the aldehyde-modified polysaccharide, ascorbic acid-crosslinked sodium hyaluronate, and stabilizer sequentially to a portion of the solvent and stir thoroughly to obtain mixture A; add the amino-modified polysaccharide to the remaining solvent and stir thoroughly to obtain solution B; S2. Add mixture A to solution B and stir thoroughly to obtain prepolymer solution; S3. The prepolymer solution is filled, allowed to stand, and sterilized to obtain Schiff base gel.
8. The method for preparing Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 7, characterized in that, Includes at least one of the following technical features: In step S1, the stirring time for preparing mixture A is 2-6 hours, and the entire process is conducted in the dark. In step S1, the stirring time for solution B is 3-8 hours; In step S3, filling includes: filling the prepolymer liquid into a pre-filled syringe, wherein the syringe is made of glass or polymer material; In step S3, the settling time is 20-30 hours; In step S3, sterilization includes: transferring the settled sample to an irradiation sterilization chamber and performing terminal sterilization using cobalt-60 or an electron beam; In step S3, the irradiated absorbed dose during the sterilization process is 10-25 kGy, preferably 15-20 kGy; In step S3, the sterilized sample is stored at 2-8°C in the dark for at least 24 hours.
9. The application of the Schiff base gel for preventing adhesions in the abdominopelvic cavity according to any one of claims 1-6, characterized in that, Postoperative anti-adhesion care applied to abdominal and pelvic surgeries.
10. The application of Schiff base gel for preventing adhesions in the abdominopelvic cavity according to claim 9, characterized in that, The application method is as follows: After abdominal and pelvic surgery, under the assistance of laparoscopy or open surgery, the hydrogel is evenly applied to the surgical wound of the abdominal and pelvic cavity using a syringe with an extension tube. After application, the Schiff base gel completely covers the abdominal and pelvic peritoneum and organ wounds, achieving long-term anti-adhesion.
